Tuesday 11/9

+ SESSION DESCRIPTION

As an infectious disease specialist with a special focus on SUD, Dr. Barocas will share his observations about what was successful in responding to COVID and offer insights on how to apply the most promising practices to the broad challenges of the national crisis of substance use disorder and its tremendous death toll. The reactor panel will share their insights on how important these observations are and how they would apply to their sector.

+ SESSION DESCRIPTION

Women with SUD who are justice involved and their families need advocacy, strategies, and support in order to move towards recovery and thrive. With experience managing the Forensic Services Program at the Philadelphia Health Management Corporation, Laurie will enlist the involvement of the attendees in a dialogue to identify strategies, solutions, and opportunities for innovation to better serve the woman who are justice involved using the lens that criminal justice is a public health concern for all of us.

+ SESSION DESCRIPTION

As people with lived experience of addiction and recovery, peer recovery coaches (PRCs) are often the lynchpin to engaging people in opioid use disorder (OUD) treatment and helping them rebuild their lives. Many states, as well as healthcare and recovery organizations, have significantly increased the use of this workforce over the past decade.

The Foundation for Opioid Response Efforts (FORE) is engaged in efforts to explore the unique challenges and experiences of PRCs across the United States so that a strong, effective workforce is developed. This session will focus on findings from a national qualitative study of peers, conducted by FORE in partnership with survey firm SSRS.

FORE plans to use the findings from this qualitative study of 47 PRCs to launch a larger, quantitative study examining the PRC workforce in different states across the nation. Hearing directly from PRCs about the supports and training they need to reach their highest potential and have a positive impact on people in treatment and recovery should be a critical component of developing policies to expand this workforce.

+ SESSION DESCRIPTION

The COVID-19 pandemic has represented changes and challenges for tribal opioid overdose prevention programs. At the same time, the process of addressing COVID-19 created new opportunities and pathways to prevention, treatment, recovery, and support care coordination.

Dr. Parker will describe the COVID-19-induced and telehealth-specific programmatic practices that support delivery of Substance Use Disorder / Opioid Use Disorder (SUD/OUD) - Opioid Overdose Prevention (OOP) services among tribal programs, tribal epidemiology centers (TECs) and urban Indian organizations during the COVID-19 pandemic.

Lori Nesbitt serves as a tribal court advocate for Yurok Tribe Opioid Response Program, a program of the Yurok Tribe Wellness Court. She will speak about how the program focuses on education, case management, prevention, youth-based activities, and demonstrates how a rural tribal community responded to COVID and reached more members with SUD.

+ SESSION DESCRIPTION

Dr. Gene Hern will speak about the Contra Costa County Pilot: EMS as an entry-point to addiction treatment, and present four novel approach strategies that involve first responders.

Josh Luftig, PA-C, will discuss how to better enlist the entire emergency department team in the life-saving work of distributing naloxone to high-risk patients. He will also describe how to expand a low-barrier, 24/7 program statewide.

Dr. Ben Zaniello will show how consistent care for MAT treatment can be monitored and improved by using cloud-based technology.

+ SESSION DESCRIPTION

Women, particularly women who are being given care and attention through prenatal care, find systems may fail them if they have concurrent SUD. Dr. Shogren will show how systems can be designed and linked to address the broader group of issues and disconnections that commonly occur when women cycle through various systems designed to treat a specific life phase but that can drop off in supporting SUD recovery. She will also bring valuable experience gained from working in rural communities.

+ SESSION DESCRIPTION

ODMAP provides near real-time suspected overdose surveillance data across jurisdictions to support public safety and public health efforts. With this information, they can mobilize an immediate response to a sudden increase, or spike in overdose events by linking first responders and relevant record management systems to a mapping tool to track overdoses to stimulate real-time response and strategic analysis across jurisdictions. This workshop will cover principles of the tool and give some examples of how ODMAP has been implemented and document its value in selected cases.

+ SESSION DESCRIPTION

The Emergency Quality (E-QUAL) Network is designed to accelerate knowledge translation by disseminating evidence-based practices in a low-burden, high-impact way. The E-QUAL Opioid Initiative aims to reduce opioid associated harm through safer prescribing and the implementation of evidence-based interventions. Since 2018, the E-QUAL Opioid Initiative has engaged over 800 EDs and 5,400 emergency clinicians in applying evidence-based quality improvement (QI) interventions to reduce opioid-associated harm. This session will illustrate the E-QUAL Opioid Initiative process, ED participants’ improvements in pain management and opioid use disorder care, and how the combination of data and QI tools facilitate practice transformation.

+ SESSION DESCRIPTION

Fentanyl is being imported in vast quantities and increasingly being incorporated into products that impact individuals using drugs many of whom are uninformed about the consequences. This session will provide up-to-date information from the DEA about illicit Fentanyl trafficking trends and measures being taken to reduce the risk to the public. The session will also bring the experience of working with individuals in the emergency department who are unprepared for fentanyl contamination. Implications for treatment and prevention will be discussed as well as the additional hazards posed in a mixed drug environment.